Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
BMC Geriatrics
Published in: BMC Geriatrics 1/2024

Open Access 01-12-2024 | Parkinson's Disease | Research

Association of dietary selenium intake and all-cause mortality of Parkinson’s disease and its interaction with blood cadmium level: a retrospective cohort study

Authors: Xinyu Tu, Na Wu, Ying Wan, Jing Gan, Zhenguo Liu, Lu Song

Published in: BMC Geriatrics | Issue 1/2024

Login to get access

Abstract

Background

Parkinson’s disease (PD) is a slowly progressive neurodegenerating disease that may eventually lead to disabling condition and pose a threat to the health of aging populations. This study aimed to explore the association of two potential risk factors, selenium and cadmium, with the prognosis of Parkinson’s disease as well as their interaction effect.

Methods

Data were obtained from the National Health and Nutrition Examination Survey (NHANES) 2005–2006 to 2015–2016 and National Death Index (NDI). Participants were classified as Parkinson’s patients by self-reported anti-Parkinson medications usage. Cox regression models and restricted cubic spline models were applied to evaluate the association between PD mortality and selenium intake level as well as blood cadmium level. Subgroup analysis was also conducted to explore the interaction between them.

Results

A total of 184 individuals were included. In full adjusted cox regression model (adjusted for age, gender, race, hypertension, pesticide exposure, smoking status and caffeine intake), compared with participants with low selenium intake, those with normal selenium intake level were significantly associated with less risk of death (95%CI: 0.18–0.76, P = 0.005) while no significant association was found between low selenium intake group and high selenium group (95%CI: 0.16–1.20, P = 0.112). Restricted cubic spline model indicated a nonlinear relationship between selenium intake and PD mortality (P for nonlinearity = 0.050). The association between PD mortality and blood cadmium level was not significant (95%CI: 0.19–5.57, P = 0.112). However, the interaction term of selenium intake and blood cadmium showed significance in the cox model (P for interaction = 0.048). Subgroup analysis showed that the significant protective effect of selenium intake existed in populations with high blood cadmium but not in populations with low blood cadmium.

Conclusion

Moderate increase of selenium intake had a protective effect on PD mortality especially in high blood cadmium populations.
Literature
1.
2.
Ye H, Robak LA, Yu M, Cykowski M, Shulman JM. Genetics and Pathogenesis of Parkinson’s Syndrome. Annu Rev Pathol. 2023;18.
3.
Greenamyre JT, Hastings TG. Biomedicine. Parkinson’s–divergent causes, convergent mechanisms. Science. 2004;304(5674):1120–2.PubMedCrossRef
4.
5.
6.
Battin EE, Brumaghim JL. Antioxidant activity of sulfur and selenium: a review of reactive oxygen species scavenging, glutathione peroxidase, and metal-binding antioxidant mechanisms. Cell Biochem Biophys. 2009;55(1).
7.
Zafar KS, Siddiqui A, Sayeed I, Ahmad M, Salim S, Islam F. Dose-dependent protective effect of selenium in rat model of Parkinson’s disease: neurobehavioral and neurochemical evidences. J Neurochem. 2003;84(3):438–46.PubMedCrossRef
8.
Khan HA. Selenium partially reverses the depletion of striatal dopamine and its metabolites in MPTP-treated C57BL mice. Neurochem Int. 2010;57(5):489–91.PubMedCrossRef
9.
Ellwanger JH, Molz P, Dallemole DR, Pereira dos Santos A, Müller TE, Cappelletti L, et al. Selenium reduces bradykinesia and DNA damage in a rat model of Parkinson’s disease. Nutrition. 2015;31(2):359–65.PubMedCrossRef
10.
Kumar S, Sharma A. Cadmium toxicity: effects on human reproduction and fertility. Rev Environ Health. 2019;34(4):327–38.PubMedCrossRef
11.
Bérglund M, Lind B, Lannerö E, Vahter M. A pilot study of lead and cadmium exposure in young children in Stockholm, Sweden: methodological considerations using capillary blood microsampling. Arch Environ Contam Toxicol. 1994;27(2):281–7.PubMedCrossRef
12.
Järup L, Akesson A. Current status of cadmium as an environmental health problem. Toxicol Appl Pharmacol. 2009;238(3):201–8.PubMedCrossRef
13.
Wang M, Chen Z, Song W, Hong D, Huang L, Li Y. A review on Cadmium exposure in the Population and intervention strategies against Cadmium Toxicity. Bull Environ Contam Toxicol. 2021;106(1):65–74.PubMedCrossRef
14.
15.
Cuypers A, Plusquin M, Remans T, Jozefczak M, Keunen E, Gielen H, et al. Cadmium stress: an oxidative challenge. Biometals. 2010;23(5):927–40.PubMedCrossRef
16.
Lorentzon E, Horvath I, Kumar R, Rodrigues JI, Tamás MJ, Wittung-Stafshede P. Effects of the toxic metals Arsenite and Cadmium on α-Synuclein aggregation in Vitro and in cells. Int J Mol Sci. 2021;22(21).
17.
Chong W, Jiménez J, McIivin M, Saito MA, Kwakye GF. α-Synuclein enhances Cadmium Uptake and Neurotoxicity via oxidative stress and caspase activated cell death mechanisms in a dopaminergic cell model of Parkinson’s Disease. Neurotox Res. 2017;32(2):231–46.PubMedCrossRef
18.
Vinceti M, Ballotari P, Steinmaus C, Malagoli C, Luberto F, Malavolti M, et al. Long-term mortality patterns in a residential cohort exposed to inorganic selenium in drinking water. Environ Res. 2016;150:348–56.PubMedCrossRef
19.
Sun H. Association of soil selenium, strontium, and magnesium concentrations with Parkinson’s disease mortality rates in the USA. Environ Geochem Health. 2018;40(1):349–57.PubMedCrossRef
20.
Ayuso-Peralta L, Jiménez-Jiménez FJ, Cabrera-Valdivia F, Molina J, Javier MR, Almazán, et al. Premorbid dietetic habits and risk for Parkinson’s disease. Parkinsonism Relat Disord. 1997;3(1):55–61.PubMedCrossRef
21.
Gellein K, Syversen T, Steinnes E, Nilsen TIL, Dahl OP, Mitrovic S, et al. Trace elements in serum from patients with Parkinson’s disease–a prospective case-control study: the Nord-Trøndelag Health Study (HUNT). Brain Res. 2008;1219:111–5.PubMedCrossRef
22.
Gupta V, Ansari NG, Garg RK, Khattri S. Determination of cd, cr, pb and ni contents among Parkinson’s disease individuals: a case-control study. Int J Neurosci. 2017;127(9):770–5.PubMedCrossRef
23.
Stefano F, Cinzia N, Marco P, Marco G, Rita G, Augusto F et al. Hair Microelement Profile as a Prognostic Tool in Parkinson’s Disease. Toxics 2016;4(4).
24.
Palacios N, Fitzgerald K, Roberts AL, Hart JE, Weisskopf MG, Schwarzschild MA, et al. A prospective analysis of airborne metal exposures and risk of Parkinson disease in the nurses’ health study cohort. Environ Health Perspect. 2014;122(9):933–8.PubMedPubMedCentralCrossRef
25.
26.
Lyra P, Machado V, Proença L, Mendes JJ, Botelho J. Tooth Loss and Blood Pressure in Parkinson’s Disease Patients: An Exploratory Study on NHANES Data. Int J Environ Res Public Health. 2021;18(9).
27.
Botelho J, Lyra P, Proença L, Godinho C, Mendes JJ, Machado V. Relationship between Blood and Standard Biochemistry Levels with Periodontitis in Parkinson’s Disease Patients: Data from the NHANES 2011–2012. J Pers Med. 2020;10(3).
28.
Zeng Z, Cen Y, Luo X. Association between blood selenium with parkinson’s disease in the US (NHANES 2011–2020). Environ Sci Pollut Res Int. 2023;30(55):117349–59.PubMedCrossRef
29.
Zeng Z, Cen Y, Xiong L, Hong G, Luo Y, Luo X. Dietary Copper Intake and Risk of Parkinson’s Disease: a Cross-sectional Study. Biol Trace Elem Res. 2023.
30.
Zeng Z, Cen Y, Wang L, Luo X. Association between dietary inflammatory index and Parkinson’s disease from National Health and Nutrition Examination Survey (2003–2018): a cross-sectional study. Front Neurosci. 2023;17:1203979.PubMedPubMedCentralCrossRef
31.
Xu S, Li W, Di Q. Association of Dietary Patterns with Parkinson’s Disease: a cross-sectional study based on the United States National Health and Nutritional Examination Survey Database. Eur Neurol. 2023;86(1):63–72.PubMedCrossRef
32.
DeMarco EC, Al-Hammadi N, Hinyard L. Exploring Treatment for Depression in Parkinson’s Patients: A Cross-Sectional Analysis. Int J Environ Res Public Health. 2021;18(16).
33.
Zhao J, Li F, Wu Q, Cheng Y, Liang G, Wang X, et al. Association between trichlorophenols and neurodegenerative diseases: a cross-sectional study from NHANES 2003–2010. Chemosphere. 2022;307(Pt 2):135743.PubMedCrossRef
34.
35.
Belvisi D, Pellicciari R, Fabbrini G, Tinazzi M, Berardelli A, Defazio G. Modifiable risk and protective factors in disease development, progression and clinical subtypes of Parkinson’s disease: what do prospective studies suggest? Neurobiol Dis. 2020;134:104671.PubMedCrossRef
36.
Ascherio A, Schwarzschild MA. The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurol. 2016;15(12):1257–72.PubMedCrossRef
37.
38.
Jiménez-Jiménez FJ, Molina JA, Arrieta FJ, Aguilar MV, Cabrera-Valdivia F, Vázquez A, et al. Decreased serum selenium concentrations in patients with Parkinson’s disease. Eur J Neurol. 1995;2(2):111–4.PubMedCrossRef
39.
Aguilar MV, Jiménez-Jiménez FJ, Molina JA, Meseguer I, Mateos-Vega CJ, González-Muñoz MJ, et al. Cerebrospinal fluid selenium and chromium levels in patients with Parkinson’s disease. J Neural Transm (Vienna). 1998;105(10–12):1245–51.PubMedCrossRef
40.
Nikam S, Nikam P, Ahaley SK, Sontakke AV. Oxidative stress in Parkinson’s disease. Indian J Clin Biochem. 2009;24(1).
41.
McIntosh KG, Cusack MJ, Vershinin A, Chen ZW, Zimmerman EA, Molho ES, et al. Evaluation of a prototype point-of-care instrument based on monochromatic x-ray fluorescence spectrometry: potential for monitoring trace element status of subjects with neurodegenerative disease. J Toxicol Environ Health A. 2012;75(21):1253–68.PubMedCrossRef
42.
Younes-Mhenni S, Aissi M, Mokni N, Boughammoura-Bouatay A, Chebel S, Frih-Ayed M, et al. Serum copper, zinc and selenium levels in Tunisian patients with Parkinson’s disease. Tunis Med. 2013;91(6):402–5.PubMed
43.
Zhao H-W, Lin J, Wang X-B, Cheng X, Wang J-Y, Hu B-L, et al. Assessing plasma levels of selenium, copper, iron and zinc in patients of Parkinson’s disease. PLoS ONE. 2013;8(12):e83060.PubMedPubMedCentralCrossRef
44.
Zhang Y-J, Sun H-L, Wang T, Liu X-X, Liu C, Li W-J et al. Selenium level does not differ in blood but increased in cerebrospinal fluid in Parkinson’s disease: a meta-analysis. Int J Neurosci. 2021;131(1).
45.
Zhou J, Zhang W, Cao Z, Lian S, Li J, Nie J et al. Association of Selenium Levels with neurodegenerative disease: a systemic review and Meta-analysis. Nutrients. 2023;15(17).
46.
Adani G, Filippini T, Michalke B, Vinceti M. Selenium and Other Trace Elements in the Etiology of Parkinson’s Disease: A Systematic Review and Meta-Analysis of Case-Control Studies. Neuroepidemiology. 2020;54(1).
47.
Zhao Y, Ray A, Portengen L, Vermeulen R, Peters S. Metal exposure and risk of Parkinson Disease: a systematic review and Meta-analysis. Am J Epidemiol. 2023;192(7):1207–23.PubMedPubMedCentralCrossRef
48.
Chang C-H, Wei C-C, Ho C-T, Liao VH-C. N-γ-(L-glutamyl)-L-selenomethionine shows neuroprotective effects against Parkinson’s disease associated with SKN-1/Nrf2 and TRXR-1 in Caenorhabditis elegans. Phytomedicine. 2021;92:153733.PubMedCrossRef
49.
Liu W, Zhang F, Liang W, Huang K, Jia C, Zhang J, et al. Integrated insight into the molecular mechanisms of selenium-modulated, MPP+-induced cytotoxicity in a Parkinson’s disease model. J Trace Elem Med Biol. 2023;79:127208.PubMedCrossRef
50.
Binte Hossain KF, Rahman MM, Sikder MT, Saito T, Hosokawa T, Kurasaki M. Inhibitory effects of selenium on cadmium-induced cytotoxicity in PC12 cells via regulating oxidative stress and apoptosis. Food Chem Toxicol. 2018;114:180–9.PubMedCrossRef
51.
52.
Fatima G, Raza AM, Hadi N, Nigam N, Mahdi AA. Cadmium in Human diseases: it’s more than just a Mere Metal. Indian J Clin Biochem. 2019;34(4):371–8.PubMedPubMedCentralCrossRef
53.
Shahkarami S, Goudarzi F, Amiri-Ardekani E, Dehghani S. Heavy metals contamination in two species of medicinal plants in the Iranian market. Int J Environ Anal Chem. 2023;103(19):8532–41.CrossRef
54.
Thai VN, Dehbandi R, Fakhri Y, Sarafraz M, Nematolahi A, Dehghani SS, et al. Potentially toxic elements (PTEs) in the Fillet of narrow-barred Spanish mackerel (Scomberomorus commerson): a global systematic review, Meta-analysis and Risk Assessment. Biol Trace Elem Res. 2021;199(9):3497–509.PubMedCrossRef
55.
Branca JJV, Pacini A, Gulisano M, Taddei N, Fiorillo C, Becatti M. Cadmium-Induced cytotoxicity: effects on Mitochondrial Electron Transport Chain. Front Cell Dev Biol. 2020;8:604377.PubMedPubMedCentralCrossRef
56.
Bovio F, Perciballi E, Melchioretto P, Ferrari D, Forcella M, Fusi P, et al. Morphological and metabolic changes in microglia exposed to cadmium: cues on neurotoxic mechanisms. Environ Res. 2024;240(Pt 1):117470.PubMedCrossRef
57.
Forte G, Alimonti A, Pino A, Stanzione P, Brescianini S, Brusa L, et al. Metals and oxidative stress in patients with Parkinson’s disease. Ann Ist Super Sanita. 2005;41(2):189–95.PubMed
58.
Seidler A, Hellenbrand W, Robra BP, Vieregge P, Nischan P, Joerg J, et al. Possible environmental, occupational, and other etiologic factors for Parkinson’s disease: a case-control study in Germany. Neurology. 1996;46(5):1275–84.PubMedCrossRef
59.
Alimonti A, Bocca B, Pino A, Ruggieri F, Forte G, Sancesario G. Elemental profile of cerebrospinal fluid in patients with Parkinson’s disease. J Trace Elem Med Biol. 2007;21(4):234–41.PubMedCrossRef
60.
Powers KM, Smith-Weller T, Franklin GM, Longstreth WT, Swanson PD, Checkoway H. Parkinson’s disease risks associated with dietary iron, manganese, and other nutrient intakes. Neurology. 2003;60(11):1761–6.PubMedCrossRef
61.
Karri V, Schuhmacher M, Kumar V. Heavy metals (pb, cd, as and MeHg) as risk factors for cognitive dysfunction: a general review of metal mixture mechanism in brain. Environ Toxicol Pharmacol. 2016;48:203–13.PubMedCrossRef
62.
Wang L, Wu K, Liu Z, Li Z, Shen J, Wu Z, et al. Selenite reduced uptake/translocation of cadmium via regulation of assembles and interactions of pectins, hemicelluloses, lignins, callose and casparian strips in rice roots. J Hazard Mater. 2023;448:130812.PubMedCrossRef
63.
Guo Y, Mao K, Cao H, Ali W, Lei D, Teng D, et al. Exogenous selenium (cadmium) inhibits the absorption and transportation of cadmium (selenium) in rice. Environ Pollut. 2021;268(Pt A):115829.PubMedCrossRef
64.
Li N, Yang L, Chen K, Kang Y, Cao Y, Du H, et al. Selenium improves the medicinal safety and quality of Bletilla striata by promoting the fixation of cadmium in root: Pot and field experiments. J Hazard Mater. 2023;459:132275.PubMedCrossRef
65.
Wang H, Sun S, Ren Y, Yang R, Guo J, Zong Y, et al. Selenite ameliorates cadmium-induced cytotoxicity through downregulation of ROS levels and Upregulation of Selenoprotein Thioredoxin Reductase 1 in SH-SY5Y cells. Biol Trace Elem Res. 2023;201(1):139–48.PubMedCrossRef
66.
Branca JJV, Morucci G, Maresca M, Tenci B, Cascella R, Paternostro F, et al. Selenium and zinc: two key players against cadmium-induced neuronal toxicity. Toxicol Vitro. 2018;48:159–69.CrossRef
67.
Sadek KM, Lebda MA, Abouzed TK, Nasr SM, Shoukry M. Neuro- and nephrotoxicity of subchronic cadmium chloride exposure and the potential chemoprotective effects of selenium nanoparticles. Metab Brain Dis. 2017;32(5):1659–73.PubMedCrossRef
68.
Trenkwalder C, Winkelmann J, Inoue Y, Paulus W. Restless legs syndrome-current therapies and management of augmentation. Nat Rev Neurol. 2015;11(8):434–45.PubMedCrossRef
69.
Abd-Elsalam S, Ebrahim S, Soliman S, Alkhalawany W, Elfert A, Hawash N, et al. Orphenadrine in treatment of muscle cramps in cirrhotic patients: a randomized study. Eur J Gastroenterol Hepatol. 2020;32(8):1042–5.PubMedCrossRef
Metadata
Title
Association of dietary selenium intake and all-cause mortality of Parkinson’s disease and its interaction with blood cadmium level: a retrospective cohort study
Authors
Xinyu Tu
Na Wu
Ying Wan
Jing Gan
Zhenguo Liu
Lu Song
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Geriatrics / Issue 1/2024
Electronic ISSN: 1471-2318
DOI
https://doi.org/10.1186/s12877-024-05000-6

Other articles of this Issue 1/2024

BMC Geriatrics 1/2024 Go to the issue

Research

Complement component C3 is associated with body composition parameters and sarcopenia in community-dwelling older adults: a cross-sectional study in Japan

Research

Loneliness among older Chinese individuals: the status quo and relationships with activity-related factors

Research

Development and psychometric testing of the Aesthetics of Everyday Life Scale in Aging (AELSA)

Research

Clinical decision support system supported interventions in hospitalized older patients: a matter of natural course and adequate timing

Research

Multimorbidity clusters in adults 50 years or older with and without a history of cancer: National Health Interview Survey, 2018

Research

Effects of an integrated ambulatory care program on healthcare utilization and costs in older patients with multimorbidity: a propensity score-matched cohort study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits